Ken Griffin Quotient LTD Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

Shares

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$0.24 - $1.2 $63,556 - $317,780	264,817 Added 550.74%	312,901 $75,000
Q1 2022 May 16, 2022	BUY	$0.94 - $2.38 $13,329 - $33,748	14,180 Added 41.82%	48,084 $57,000
Q4 2021 Feb 14, 2022	BUY	$1.89 - $3.12 $27,049 - $44,653	14,312 Added 73.05%	33,904 $87,000
Q3 2021 Nov 15, 2021	SELL	$2.34 - $3.77 $72,036 - $116,059	-30,785 Reduced 61.11%	19,592 $46,000
Q2 2021 Aug 16, 2021	BUY	$3.48 - $4.45 $97,718 - $124,956	28,080 Added 125.94%	50,377 $183,000
Q1 2021 May 17, 2021	SELL	$3.57 - $6.2 $121,922 - $211,742	-34,152 Reduced 60.5%	22,297 $82,000
Q4 2020 Feb 16, 2021	BUY	$4.4 - $7.32 $11,743 - $19,537	2,669 Added 4.96%	56,449 $295,000
Q3 2020 Nov 16, 2020	SELL	$4.38 - $8.35 $888,154 - $1.69 Million	-202,775 Reduced 79.04%	53,780 $277,000
Q1 2020 May 15, 2020	BUY	$2.54 - $9.38 $42,928 - $158,531	16,901 Added 7.05%	256,555 $1.01 Million
Q4 2019 Feb 14, 2020	SELL	$7.07 - $9.51 $169,927 - $228,572	-24,035 Reduced 9.11%	239,654 $2.28 Million
Q3 2019 Nov 14, 2019	BUY	$7.77 - $11.26 $246,417 - $357,099	31,714 Added 13.67%	263,689 $2.05 Million
Q2 2019 Aug 14, 2019	SELL	$7.91 - $10.25 $29,939 - $38,796	-3,785 Reduced 1.61%	231,975 $2.17 Million
Q1 2019 May 15, 2019	BUY	$6.0 - $11.07 $827,580 - $1.53 Million	137,930 Added 140.99%	235,760 $0
Q3 2018 Nov 13, 2018	SELL	$6.57 - $8.31 $95,041 - $120,212	-14,466 Reduced 12.88%	97,830 $0
Q2 2018 Aug 10, 2018	BUY	$3.93 - $8.93 $441,323 - $1 Million	112,296 New	112,296 $0

Others Institutions Holding QTNT

# of Institutions

1

Shares Held

1.71K

Call Options Held

0

Put Options Held

0

Brewin Dolphin LTD London, X0

1.71K
Shares

$68
0.0% of portfolio

About Quotient Ltd

Ticker QTNT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Description
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological di...

More about QTNT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.